Patents by Inventor Azra Raza

Azra Raza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC MOLECULES TO TARGET THE FIRST CELL
    Publication number: 20250051475
    Abstract: The subject matter described herein relates to a method of treating cancer in a subject in need thereof using a bispecific molecule recognizing two antigen markers of different tissue lineages on the surface of The First Cell.
    Type: Application
    Filed: December 30, 2022
    Publication date: February 13, 2025
    Inventors: Azra RAZA, Abdullah M. ALI
  • Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies
    Patent number: 11186877
    Abstract: The present invention relates to utilizing terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, in particular myelodyplastic syndromes. The present invention relates to identifying patients with myelodysplastic syndromes at risk for poor survival/outcomes who would benefit from aggressive treatment, by characterizing their TED profile using protein and gene expression markers and combinations thereof.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 30, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Azra Raza, Abdullah Mahmood Ali, Naomi Galili
  • Methods and compositions for treatment of cancer
    Patent number: 10576050
    Abstract: The invention discloses a method of treating cancer refractory to an anticancer agent comprising administering to a cancer patient a pharmaceutical composition comprising at least one compound of Formula 1 Where R1 is selected from the group consisting of —NH2, —NH—CH2—COOH, —NH—CH(CH3)—COOH, —NH—C(CH3)2—COOH, —NH—CH2—CH2—OH and —N—(CH2CH2OH)2 or a pharmaceutically acceptable salt of such a compound, and an anticancer agent.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 3, 2020
    Assignee: ONCONOVA THERAPEUTICS, INC.
    Inventors: Manoj Maniar, Azra Raza, Francois Wilhelm
  • TERMINAL ERYTHROID DIFFERENTIATION AS A BIOMARKER FOR PROGNOSIS AND TREATMENT, AND THERAPEUTIC TARGET IN MYELOID MALIGNANCIES
    Publication number: 20190187159
    Abstract: The present invention relates to utilizing terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, in particular myelodyplastic syndromes. The present invention relates to identifying patients with myelodysplastic syndromes at risk for poor survival/outcomes who would benefit from aggressive treatment, by characterizing their TED profile using protein and gene expression markers and combinations thereof.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 20, 2019
    Inventors: Azra Raza, Abdullah Mahmood Ali, Naomi Galili
  • METHODS AND COMPOSITIONS FOR PREDICTING THERAPEUTIC EFFICACY OF KINASE INHIBITORS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OR RELATED DISORDERS
    Publication number: 20160102363
    Abstract: The invention discloses a diagnostic method for predicting the therapeutic efficacy of a broad specificity kinase inhibitor in a subject with refractory cancer comprising determining the locus-specific DNA methylation profile of the subject, wherein the locus-specific DNA methylation profile predicts the therapeutic efficacy of a broad specificity kinase inhibitor for treatment of a subject with refractory cancer.
    Type: Application
    Filed: May 28, 2014
    Publication date: April 14, 2016
    Applicants: ONCONOVA THERAPEUTICS, INC., THE TRUSTEES OF COLUMBIA UNVIERSITY IN THE CITY OF NEW YORK
    Inventors: BENJAMIN TYCKO, AZRA RAZA, FRANCOIS WILHELM
  • METHODS AND COMPOSTIONS FOR TREATMENT OF CANCER
    Publication number: 20150313859
    Abstract: The invention discloses a method of treating cancer refractory to an anticancer agent comprising administering to a cancer patient a pharmaceutical composition comprising at least one compound of Formula 1 Where R1 is selected from the group consisting of —NH2, —NH—CH2—COOH, —NH—CH(CH3)—COOH, —NH—C(CH3)2—COOH, —NH—CH2—CH2—OH and —N—(CH2CH2OH)2 or a pharmaceutically acceptable salt of such a compound, and an anticancer agent.
    Type: Application
    Filed: December 6, 2013
    Publication date: November 5, 2015
    Applicants: ONCONOVA THERAPEUTICS, INC., THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: MANOJ MANIAR, AZRA RAZA, FRANCOIS WILHELM
  • Novel retrovirus associated with myelodysplastic syndromes and uses thereof
    Publication number: 20060228700
    Abstract: The present invention relates first, to the identification of a novel retrovirus and the novel nucleotide sequences encoding a retroviral polymerase gene (POL nucleotides) associated with the existence of MDS and MDS associated disorders. The present invention further relates to methods for using the MDS associated retroviral nucleotides for the detection of MDS and MDS associated disorders in patient samples. The present invention also relates to methods for using and targeting the MDS associated retroviral POL nucleotides in gene therapy protocols for the treatment of MDS and MDS associated disorders in patients in need of such treatment. The present invention further relates to diagnostic protocols and kits for the detection of MDS and MDS associated disorders in tissue samples.
    Type: Application
    Filed: March 21, 2006
    Publication date: October 12, 2006
    Inventors: Azra Raza, Harvey Preisler
  • Retrovirus associated with myelodysplastic syndromes and uses thereof
    Patent number: 7074553
    Abstract: The present invention relates first, to the identification of a novel retrovirus and the novel nucleotide sequences encoding a retroviral polymerase gene (POL nucleotides) associated with the existence of MDS and MDS associated disorders. The present invention further relates to methods for using the MDS associated retroviral nucleotides for the detection of MDS and MDS associated disorders in patient samples. The present invention also relates to methods for using and targeting the MDS associated retroviral POL nucleotides in gene therapy protocols for the treatment of MDS and MDS associated disorders in patients in need of such treatment. The present invention further relates to diagnostic protocols and kits for the detection of MDS and MDS associated disorders in tissue samples.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: July 11, 2006
    Assignee: Rush University Medical Center
    Inventors: Azra Raza, Azra Raza, legal representative, Harvey D. Preisler, deceased
  • Novel retrovirus associated with myelodysplastic syndromers and uses thereof
    Publication number: 20040106103
    Abstract: The present invention relates first, to the identification of a novel retrovirus and the novel nucleotide sequences encoding a retroviral polymerase gene (POL nucleotides) associated with the existence of MDS and MDS associated disorders. The present invention further relates to methods for using the MDS associated retroviral nucleotides for the detection of MDS and MDS associated disorders in patient samples. The present invention also relates to methods for using and targeting the MDS associated retroviral POL nucleotides in gene therapy protocols for the treatment of MDS and MDS associated disorders in patients in need of such treatment. The present invention further relates to diagnostic protocols and kits for the detection of MDS and MDS associated disorders in tissue samples.
    Type: Application
    Filed: May 28, 2003
    Publication date: June 3, 2004
    Inventors: Azra Raza, Harvey Preisler